Oncology and Hematology - Prova Education

177-192 of 219

Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
Luis Paz-Ares, MD, PhD; Helena Yu, MD
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CE
Warm Autoimmune Hemolytic Anemia: How Antibody-Based Therapies Are Revolutionizing Its Management
Caroline Piatek, MD; Irina Murakhovskaya, MD
0.25 credits
- Caroline Piatek, MD
- Irina Murakhovskaya, MD
0.25 credits
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and Hematology
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and Hematology
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and Hematology
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and Hematology
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Oncology and Hematology
Updates from Apa-RP: Apalutamide and ADT in High-Risk Localized Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Oncology and Hematology
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Oncology and Hematology
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CE
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
0.25 credits
- Meghan Mooradian, MD
0.25 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
0.25 credits
- Helena Yu, MD
0.25 credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD; Pasi Antero Jänne, MD, PhD
0.50 credits
- Jyoti Patel, MD
- Pasi Antero Jänne, MD, PhD
0.50 credits

12/8